

CHAMPIONS ONCOLOGY, INC.

Form 8-K

July 23, 2015

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): July 2, 2015

**CHAMPIONS ONCOLOGY, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

**0-17263**

**52-1401755**

(State or Other Jurisdiction (Commission File Number) (IRS Employer  
of Incorporation)

Identification No.)

**1 University Plaza, Suite 307, Hackensack, New Jersey 07601**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(201) 808-8400**

**Not applicable**

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 5.02. Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.**

On July 2, 2015, James J. McGorry, the Executive Vice President and General Manager, Translational Oncology Solutions of Champions Oncology, Inc. (the “**Company**”) resigned from the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CHAMPIONS  
ONCOLOGY, INC.**  
(Registrant)

Date: July 23, 2015      By: /s/ Joel  
Ackerman  
Joel Ackerman  
Chief  
Executive  
Officer